Cytel to hold Complex Innovative Trial Design Symposium

18 Oct 2019

Experts to discuss innovative solutions to rare disease clinical trials.

Cytel has announced that the Complex Innovative Trial Design Symposium and East Training will take place 6–7 November at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.

Cytel to hold Complex Innovative Trial Design Symposium

Cytel has hosted the annual Complex Innovative Trial Design Symposium and East Training since 2011 to connect global thought leaders and innovators from the pharmaceutical industry in order to facilitate the exchange of ideas and reveal new insights on the latest developments in adaptive clinical trial designs. The event also plays a key role in guiding the continual evolution of Cytel’s East platform, the industry-standard software for adaptive clinical trial design and analysis. Amongst the list of guest speakers will be leaders from Pfizer, Takeda and Servier, as well as statistical experts from Cytel, Alexion and Axio.

This year’s symposium will focus on overcoming the acute challenges associated with clinical trials for rare diseases, with an emphasis on how innovative, adaptive clinical trial designs can be exploited to maximize trial efficiency, accommodate specialized data requirements and enhance rare disease trial success rates. The latest insights and detailed case studies will be shared through a series of engaging presentations, and participants will also have the opportunity to actively participate in an East training session on day two.

Currently, rare diseases affect around 350 million patients worldwide, with 90% of rare diseases still without an approved therapy. In addition, scarce patient resources and lack of disease knowledge regarding the best endpoints and treatment effect size makes clinical development for new and effective therapeutics for rare diseases especially difficult.

“To overcome the myriad of clinical trial pain points presented by rare diseases, we need to think creatively and adopt a knowledge-sharing approach to the clinical development process,” said Yannis Jemiai, Chief Scientific Officer at Cytel. “The symposium will offer a key space to facilitate peer-to-peer exchanges, ideation, and sharing of practical solutions. We are driving forward novel experimental designs and statistical approaches for better clinical outcomes in patients with rare disorders.”

Delegates will have the opportunity to learn about a range of novel methodological advancements in the rare disease trial space, including:

  • The use of natural history data in clinical trials for rare diseases
  • The PREVENT trial for Neuromyelitis optica spectrum disorder (NMOSD)
  • Historical control information borrowing.
  • The in-depth East software training workshop that will take place on day two will guide participants through the extensive range of powerful trial design tools within East, keeping them up to date on the software platform’s latest developments.

    Read More

    Related news

    The game is on for connected devices

    The game is on for connected devices

    20 Feb 2020

    Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma.

    Read more 
    CPhI South East Asia rescheduled for July 2020

    CPhI South East Asia rescheduled for July 2020

    18 Feb 2020

    Event move ensures extra precautions and safety measures taken

    Read more 
    Report predicts booming ASEAN generics export market for 2020

    Report predicts booming ASEAN generics export market for 2020

    13 Feb 2020

    The changing opportunities are attributed to rising GMP standards and increased regional harmonization.

    Read more 
    Innovation awarded at Pharmapack

    Innovation awarded at Pharmapack

    10 Feb 2020

    Innovations across primary and secondary packaging, drug delivery devices, and machinery acknowledged in Exhibitor Innovations, with Health Product Awards for patient-centricity and eco-design.

    Read more 
    Digital value-added medicines - a key driver for 2020

    Digital value-added medicines - a key driver for 2020

    29 Jan 2020

    Pharmapack also identifies waste management and the use of blockchain as key trends for the year ahead.

    Read more 
    CPhI and AAPS partner to expand expert scientific content at CPhI North America

    CPhI and AAPS partner to expand expert scientific content at CPhI North America

    10 Jan 2020

    CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

    Read more 
    Innovation and regulatory harmonisation to drive Indian pharma in 2020

    Innovation and regulatory harmonisation to drive Indian pharma in 2020

    18 Dec 2019

    Experts suggest the continued goal of aligning India to Western regulatory standards will help the country sustain significant increases in exports.

    Read more 
    Connectivity, customization and sustainability driving packaging and drug delivery in 2020

    Connectivity, customization and sustainability driving packaging and drug delivery in 2020

    4 Dec 2019

    Pharmapack 2020 gathering top specialists and pioneers to exchange their vision on best strategies to tackle key challenges.

    Read more 
    Worldwide event predicts global pharma trends for 2020

    Worldwide event predicts global pharma trends for 2020

    27 Nov 2019

    Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.

    Read more 
    India pharma forecast to grow strongly in 2020

    India pharma forecast to grow strongly in 2020

    22 Nov 2019

    The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.

    Read more